What's new in molecular genetic pathology 2022: immune checkpoint inhibitor biomarkers and select solid tumors
Predictive biomarker testing plays a critical role in targeted immuno-oncology, including the use of immune checkpoint inhibitors (ICI) for various solid tumors. Molecular advancements in cancers of the breast, kidney and brain have continued to propel tumor classification and precision therapy.
Saved in:
Main Authors: | Patricia C. Tsang (Author), Guoli Chen (Author) |
---|---|
Format: | Book |
Published: |
Korean Society of Pathologists & the Korean Society for Cytopathology,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
What's new in molecular genetic pathology 2021: solid tumors and NGS panel selection
by: Guoli Chen, et al.
Published: (2021) -
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
by: Rilan Bai, et al.
Published: (2020) -
Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors
by: Stefano Lucà, et al.
Published: (2024) -
Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer
by: Jie Yao, et al.
Published: (2024) -
Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors
by: Danielle Gilbert, et al.
Published: (2023)